GRACE :: Lung Cancer

anti-PD1

5 Key Points on Immune Checkpoint Inhibitors for Lung Cancer: Game Changer or Just Leveling Up?

Share

Just last week, I ranked the development of immunotherapies as the leading development in lung cancer in 2013. I don’t consider 2013 to be the clear turning point for immunotherapies in lung cancer: they have been the subject of interest and research for many years, and ASCO 2012 really marks their breakout from niche idea to more widespread credibility. But if 2012 was the real launchpad, 2013 saw the rocket really take off. The question is where is it really going?

I’ve had the opportunity to put more than a dozen patients on immune checkpoint inhibitors (anti-PD1, anti-PDL1) over the past 12-18 months, and in that time I’ve been able to combine my real life clinical experience with more data from other agents. At this point, I’d like to offer some preliminary projections on what we should expect from immunotherapies. 

Continue reading


Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Share

Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.


How should we integrate new immunotherapies into treatment strategies for lung cancer?

Share

Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.


Can we harness our immune system to fight NSCLC?

Share

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

Discuss this post in the GRACE Discussion Forums


Dr. Geoffrey Oxnard on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Share

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.


Dr. Karen Kelly on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Share

Dr. Karen Kelly of the University of California, Davis, provides her view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.


Dr. Phil Bonomi on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Share

Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.


Dr. Leighl’s Highlights in Lung Cancer 2012, Part 4: Squamous Cell NSCLC and Anti-PD1 Immunotherapy

Share

Anti-PD1 FigureDr. Leighl continued her presentation on “Highlights in Lung Cancer, 2012″ with a discussion of the challenges that many patients with squamous NSCLC face, typically not having a cancer with a “driver mutation” like an EGFR mutation or an ALK rearrangement.  However, she notes that several new targets that may be especially relevant for patients with squamous NSCLC are becoming the subject of growing clinical research. In addition, one exciting development from 2012 that appears perhaps particularly beneficial for patients with squamous NSCLC is anti-PD1 antibody immunotherapy, an agent now known as nivolumab.  

Here are the video and audio versions of the podcast for this portion of the webinar, along with the associated figures:

Leighl Highlights in LC 2012 Pt 4 Squam and Anti-PD1 Audio Podcast

Leighl Highlights in LC 2012 Pt 4 Squam and Anti-PD1 Figures

Continue reading


Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

Share

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.


Dr. Greg Riely on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

Share

Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Other Resources